New pill aims to slow Parkinson's progression in Early-Stage patients
Disease control
Not yet recruiting
This study tests an oral drug called GT-02287 in 111 people with early Parkinson's disease. Participants will receive either a low dose, high dose, or placebo for 48 weeks. The goal is to see if the drug improves daily movement and motor symptoms, and to check its safety and effe…
Phase: PHASE2 • Sponsor: Gain Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC